OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1672
- Registration Number
- NCT02847624
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02679469
- Locations
- 🇯🇵
Kyusyu, Region, Japan
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 77
- Registration Number
- NCT02554721
A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Phase 2
Completed
- Conditions
- Bacterial Enteritis
- Interventions
- Drug: OPS-2071 tablet
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT02473393
A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
Phase 1
Completed
- Conditions
- Bacterial Enteritis
- Interventions
- Drug: 14C-OPS-2071
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT02440633
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT02382276
- Locations
- 🇯🇵
Kinki, Region, Japan
🇯🇵Hokkaido, Region, Japan
🇯🇵Chubu, Region, Japan
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 678
- Registration Number
- NCT02364947
- Locations
- 🇯🇵
Tohoku, Region, Japan
🇯🇵Tyugoku, Region, Japan
🇯🇵Hokkaido, Region, Japan
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo OintmentDrug: 3% OPA-15406 OintmentDrug: 0.3% OPA-15406 OintmentDrug: 1% OPA-15406 Ointment
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02334787
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT02331680
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT02293993
- Locations
- 🇯🇵
Kanto, Region, Japan
🇯🇵kinki Region, Kyoto, Japan
🇯🇵Kyusyu, Region, Japan
© Copyright 2025. All Rights Reserved by MedPath